From adenoma to CRC stages: the oral-gut microbiome axis as a source of potential microbial and metabolic biomarkers of malignancy

[1]  T. Poškus,et al.  Tissue vs. Fecal-Derived Bacterial Dysbiosis in Precancerous Colorectal Lesions: A Systematic Review , 2023, Cancers.

[2]  Meng Shao,et al.  Lactate: A regulator of immune microenvironment and a clinical prognosis indicator in colorectal cancer , 2022, Frontiers in Immunology.

[3]  Therese G. Kellgren,et al.  Parvimonas micra is associated with tumour immune profiles in molecular subtypes of colorectal cancer , 2022, Cancer Immunology, Immunotherapy.

[4]  Lianzhong Yan,et al.  Oral-Intestinal Microbiota in Colorectal Cancer: Inflammation and Immunosuppression , 2022, Journal of inflammation research.

[5]  X. Mo,et al.  The Application of Metabolomics in Recent Colorectal Cancer Studies: A State-of-the-Art Review , 2022, Cancers.

[6]  Xuchao Wang,et al.  A New Biomarker of Fecal Bacteria for Non-Invasive Diagnosis of Colorectal Cancer , 2021, Frontiers in Cellular and Infection Microbiology.

[7]  K. Howell,et al.  The salivary microbiome shows a high prevalence of core bacterial members yet variability across human populations , 2021, bioRxiv.

[8]  S. Choi,et al.  Analysis of changes in microbiome compositions related to the prognosis of colorectal cancer patients based on tissue-derived 16S rRNA sequences , 2021, Journal of translational medicine.

[9]  S. Choi,et al.  Analysis of changes in microbiome compositions related to the prognosis of colorectal cancer patients based on tissue-derived 16S rRNA sequences , 2021, Journal of Translational Medicine.

[10]  L. Tenori,et al.  Fecal metabolomic profiles: A comparative study of patients with colorectal cancer vs adenomatous polyps , 2021, World journal of gastroenterology.

[11]  Yan-lai Sun,et al.  Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma , 2021, Gut.

[12]  R. Burcelin,et al.  Oral Microbiota: A Major Player in the Diagnosis of Systemic Diseases , 2021, Diagnostics.

[13]  Pengfei Xu,et al.  Global colorectal cancer burden in 2020 and projections to 2040 , 2021, Translational oncology.

[14]  Wu Ning,et al.  Metabolic profiling analysis for clinical urine of colorectal cancer , 2021, Asia-Pacific journal of clinical oncology.

[15]  A. Amedei,et al.  Diving into inflammation: a pilot study exploring the dynamics of the immune-microbiota axis in ileal tissue layers of patients with Crohn's disease. , 2021, Journal of Crohn's & colitis.

[16]  Mia Yang Ang,et al.  Parvimonas micra, Peptostreptococcus stomatis, Fusobacterium nucleatum and Akkermansia muciniphila as a four-bacteria biomarker panel of colorectal cancer , 2021, Scientific Reports.

[17]  P. Yi,et al.  Metabolism of Amino Acids in Cancer , 2021, Frontiers in Cell and Developmental Biology.

[18]  Azimeh Izadi,et al.  Anticancer effects of bifidobacteria on colon cancer cell lines , 2020, Cancer cell international.

[19]  Y. Nagakawa,et al.  Urinary charged metabolite profiling of colorectal cancer using capillary electrophoresis-mass spectrometry , 2020, Scientific Reports.

[20]  W. D. de Vos,et al.  Unravelling lactate‐acetate and sugar conversion into butyrate by intestinal Anaerobutyricum and Anaerostipes species by comparative proteogenomics , 2020, Environmental microbiology.

[21]  M. Claesson,et al.  Non-specific amplification of human DNA is a major challenge for 16S rRNA gene sequence analysis , 2020, Scientific Reports.

[22]  R. Palmqvist,et al.  Parvimonas micra as a putative non-invasive faecal biomarker for colorectal cancer , 2020, Scientific Reports.

[23]  A. Wu,et al.  Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study , 2020, Breast Cancer Research and Treatment.

[24]  V. Vymetálková,et al.  Colorectal Adenomas—Genetics and Searching for New Molecular Screening Biomarkers , 2020, International journal of molecular sciences.

[25]  R. Fani,et al.  Significant and Conflicting Correlation of IL-9 With Prevotella and Bacteroides in Human Colorectal Cancer , 2020, bioRxiv.

[26]  Y. Hahn,et al.  Metagenomic analysis of the human microbiome reveals the association between the abundance of gut bile salt hydrolases and host health , 2020, Gut microbes.

[27]  J. Cubiella,et al.  Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer , 2020, Cancers.

[28]  Takuji Yamada,et al.  Significance of the gut microbiome in multistep colorectal carcinogenesis , 2020, Cancer science.

[29]  J. Prados,et al.  Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer , 2019, Scientific Reports.

[30]  N. Habermann,et al.  Plasma metabolites associated with colorectal cancer stage: Findings from an international consortium , 2019, International journal of cancer.

[31]  C. Theriot,et al.  Diversification of host bile acids by members of the gut microbiota , 2019, Gut microbes.

[32]  M. Scharl,et al.  Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy , 2019, EBioMedicine.

[33]  Jun Yu,et al.  Gut microbiota in colorectal cancer: mechanisms of action and clinical applications , 2019, Nature Reviews Gastroenterology & Hepatology.

[34]  Tomoyoshi Soga,et al.  Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer , 2019, Nature Medicine.

[35]  Xinxiang Li,et al.  Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer , 2019, Theranostics.

[36]  Jun Yu,et al.  International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis , 2019, Gut.

[37]  Jianguo Xia,et al.  MetaboAnalystR 2.0: From Raw Spectra to Biological Insights , 2019, Metabolites.

[38]  J. McQuade,et al.  Modulating the microbiome to improve therapeutic response in cancer. , 2019, The Lancet. Oncology.

[39]  S. Rampelli,et al.  Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis , 2018, Scientific Reports.

[40]  E. R. Amedei.  The Role of the Microbiota in the Genesis of Gastrointestinal Cancers , 2018, Frontiers in Anti-Infective Drug Discovery: Volume 7.

[41]  R. Fani,et al.  Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study , 2018, Front. Microbiol..

[42]  S. Clinton,et al.  Fusobacterium’s link to colorectal neoplasia sequenced: A systematic review and future insights , 2017, World journal of gastroenterology.

[43]  T. Ohkusa,et al.  Characterization of Fusobacterium varium Fv113-g1 isolated from a patient with ulcerative colitis based on complete genome sequence and transcriptome analysis , 2017, PloS one.

[44]  J. Goedert,et al.  Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations , 2016, PloS one.

[45]  F. Ryan,et al.  Tumour-associated and non-tumour-associated microbiota in colorectal cancer , 2016, Gut.

[46]  A. Taddei,et al.  The interplay between the microbiome and the adaptive immune response in cancer development , 2016, Therapeutic advances in gastroenterology.

[47]  S. Meier,et al.  Strategy for Nuclear-Magnetic-Resonance-Based Metabolomics of Human Feces. , 2015, Analytical chemistry.

[48]  Patrick D Schloss,et al.  Structure of the gut microbiome following colonization with human feces determines colonic tumor burden , 2014, Microbiome.

[49]  M. Toyota,et al.  Fusobacterium in colonic flora and molecular features of colorectal carcinoma. , 2014, Cancer research.

[50]  S. Winter,et al.  Why related bacterial species bloom simultaneously in the gut: principles underlying the ‘Like will to like’ concept , 2014, Cellular microbiology.

[51]  M. Meyerson,et al.  Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. , 2013, Cell host & microbe.

[52]  Amy M. Sheflin,et al.  Stool Microbiome and Metabolome Differences between Colorectal Cancer Patients and Healthy Adults , 2013, PloS one.

[53]  Shuji Ogino,et al.  Colorectal cancer: a tale of two sides or a continuum? , 2012, Gut.

[54]  G. Trinchieri.  Cancer and inflammation: an old intuition with rapidly evolving new concepts. , 2012, Annual review of immunology.

[55]  K. Ray.  Colorectal cancer: Fusobacterium nucleatum found in colon cancer tissue—could an infection cause colorectal cancer? , 2011, Nature Reviews Gastroenterology &Hepatology.

[56]  A. Onitilo,et al.  Tumor-Related Hyponatremia , 2007, Clinical Medicine & Research.

[57]  H. Senn,et al.  Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. , 2006, Analytical chemistry.

[58]  P. Vaupel,et al.  Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. , 2004, The oncologist.

[59]  T. Ohkusa,et al.  Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis , 2003, Gut.

[60]  T. Ohkusa,et al.  Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species‐specific antibody , 2002, Journal of gastroenterology and hepatology.

[61]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[62]  R. Beart,et al.  Staging of colorectal cancer. , 1992 .

[63]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[64]  C. Bonithon-Kopp,et al.  Fatty acid composition of adipose tissue and colorectal cancer: a case-control study. , 2015, The American journal of clinical nutrition.

[65]  U. Manne,et al.  Development and progression of colorectal neoplasia. , 2010, Cancer biomarkers : section A of Disease markers.

[66]  T. Miller,et al.  NMR detection of 13CH313COOH from 3-13C-glucose: a signature for Bifidobacterium fermentation in the intestinal tract. , 1998, The Journal of nutrition.